Welcome members and clients of OMMP PIF. Due to increased costs, our website has moved to this server, Thanks go to our Friend and colleague, Wired57, for making this possible. If you have any questions or concerns, please start a new topic in 
Thank you 
09-28-2017, 07:09 AM
Zynerba Pharma Wins Big on CannabisTrial
<p class="post-meta">
By <a class="vcard author url" href="http://247wallst.com/author/chris-lange/" itemprop="author" itemscope="" itemtype="http://schema.org/Person" title="Posts by Chris Lange"><span class="fn" itemprop="name">Chris Lange</a></span> September 28, 2017
Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) shares saw a huge gain early on Thursday after the firm announced positive results from its mid-stage cannabinoid trial. Specifically, the firm was evaluating ZYN002 cannabidiol (CBD) gel in pediatric and adolescent patients with fragile X syndrome (FXS).
For some quick background: fragile X syndrome is an autism spectrum disorder affecting one in 4,000 males and one in 8,000 females. It is the most common inherited intellectual disability in males and a significant cause of intellectual disability in females.
http://247wallst.com/healthcare-business...bis-trial/